Novo Nordisk Files for Regulatory Approval of Faster-Acting Insulin Aspart in the US for the Treatment of Type 1 and 2 Diabetes
Bagsværd, Denmark, 9 December 2015 - Novo Nordisk today announced the submission of the New Drug Application (NDA) for faster-acting insulin aspart to the US Food and Drug Administration (FDA). Faster-acting insulin aspart is a mealtime insulin for...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Diabetes | Diabetes Type 1 | Endocrinology | Food and Drug Administration (FDA) | Insulin | New Drug Applications | Pharmaceuticals